Summary of Foghorn Therapeutics FY Conference Call Company Overview - **Company**: Foghorn Therapeutics (NasdaqGM:FHTX) - **Industry**: Biotechnology, specifically focused on oncology and chromatin regulatory systems - **Key Personnel**: Dr. Adrian Gottschalk, President and CEO Core Points and Arguments - **Clinical Stage Focus**: Foghorn is a clinical-stage biotech company primarily focused on oncology, utilizing the chromatin regulatory system, which has been found to play a significant role in various diseases, including cancer, autoimmunity, and neurodegeneration [3][4] - **Drug Development**: The company has developed capabilities in protein degradation, with most advanced proprietary programs being protein degraders. The chromatin regulatory system is crucial for gene expression regulation [5][6] - **Partnership with Eli Lilly**: Foghorn has a 50/50 partnership with Eli Lilly on the FHD-909 program, which is currently in the dose escalation phase. The collaboration is significant, being one of the largest preclinical oncology deals [7][8] - **Pipeline Progress**: Foghorn is on track for IND-enabling studies for its selective CBP and EP300 programs later this year, with an expected IND for an I&I program in 2027 [7][8][36] Clinical Trials and Data - **SMARCA2 Program**: The SMARCA2 program is currently dosing escalated, with sites open in the US, Japan, France, Germany, Spain, and South Korea. The maximum tolerated dose has not yet been reached [9][10] - **Patient Demographics**: The study focuses on non-small cell lung cancer patients with SMARCA4 mutations, particularly those in the fourth or fifth line of treatment, indicating a high unmet medical need [12][13][14] - **Efficacy Data**: Preliminary data suggests that patients with SMARCA4 mutations have significantly lower response rates and overall survival compared to wild-type patients, highlighting the need for effective treatments in this population [13][14][15] Proprietary Pipeline - **CBP and EP300 Programs**: Foghorn is developing selective protein degraders for CBP and EP300, which are histone acetyltransferases. The lead molecule for CBP, FHT-171, has shown promising pre-development results [18][19][20] - **Long-acting Formulations**: The company is working on long-acting injectable formulations for its VHL-based degraders, aiming for subcutaneous delivery once a week [23][29] - **ARID1B Degrader**: Foghorn is also developing an ARID1B degrader, which has shown potential across various solid tumor malignancies. The goal is to achieve in vivo proof of concept by 2026 [31][32][34] Financial Position - **Funding**: Foghorn recently completed a registered direct offering of $50 million, which is expected to cover operational expenses for approximately two quarters. This offering was priced at a 30% premium to the trading price at the time, indicating investor confidence [37][38] Additional Insights - **Market Positioning**: The company is strategically positioned to address significant unmet needs in oncology, particularly for patients with specific genetic mutations [12][14] - **Future Directions**: Foghorn is exploring induced proximity mechanisms and has plans to provide updates on these developments in the coming years [36] This summary encapsulates the key points discussed during the Foghorn Therapeutics FY Conference Call, highlighting the company's focus on innovative oncology treatments and its strategic partnerships.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Eli Lilly and Company (NYSE:LLY) FY Conference March 02, 2026 03:10 PM ET Company ParticipantsLucas Montarce - EVP and CFOMichael Czapar - SVP of Investor RelationsConference Call ParticipantsSteve Scala - Pharmaceutical AnalystNone - AnalystNone - AnalystSteve ScalaOne's 46th Annual Healthcare Conference. We are absolutely delighted to have Eli Lilly back at the conference again this year. Representing the company is Lucas Montarce, who is the CFO, as well as Mike Czapar, who is the Head of Investor Relati ...

Eli Lilly on track to launch oral obesity drug in second quarter, pending US approval | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake [Purchase Licensing Rights, opens new tab]- Companies[Eli Lilly and Co]FollowMarch 2 (Reuters) - Eli Lilly [(LLY.N), opens new tab] CFO Lucas Montarce said on Monday it is pr ...

Key Takeaways Eli Lilly received a positive CHMP opinion to expand Olumiant use in adolescents with severe AA.Phase III data showed 42% patients with severe AA achieved at least 80% scalp hair coverage at 36 weeks.Olumiant recorded sales worth $1.01B in 2025; U.S. adolescent decision expected in H2 2026.Eli Lilly (LLY) and Incyte (INCY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending the approval of the e ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare company in the world, as its valuation hovers around $1 trillion. It has generated fantastic gains for investors, rising by more than 400% in just the past five years. Those are terrific returns for a stock that's a fairly safe blue chip investment. But with such impressive gains, you may be wondering whether it's too late to invest in the stock, whether there's still room for it to rise, or if it's due for a correction. Below, I'll look to answer thos ...

In this articleNVOLLYNVONovo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capacities to make the newly launched Wegovy pill, the Danish drugmaker said Monday. The news comes about two months after Novo launched its blockbuster weight loss drug Wegovy in pill form in the U.S. market, in what has been described as one of the strongest launches ever. "With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities f ...

Quick Read Eli Lilly (LLY) beat Q4 EPS estimates by 12%. Zepbound holds nearly 70% of new obesity prescriptions. Lilly CEO and 12 executives collectively purchased $104M in shares during February. Lilly expects FDA approval for its oral GLP-1 orforglipron in Q2 2026. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE. Eli Lilly (NYSE: LLY) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares dur ...

Key Takeaways Novo Nordisk stock fell 21% after CagriSema lost to Zepbound in the phase III REDEFINE 4 obesity study.Lilly's orforglipron beat Rybelsus in ACHIEVE-3, cutting A1C by 2.2% and weight by 9.2% at 52 weeks.Novo Nordisk plans to cut U.S. list prices of Wegovy, Ozempic and Rybelsus to $675 monthly by 2027.Novo Nordisk (NVO) has endured a brutal week, with its shares plunging 21% after a series of disappointing clinical results and mounting pricing pressures erased virtually all the gains accumulate ...

The drug and biotech sector has recovered somewhat in 2026 after remaining muted for most of 2025. Drug pricing agreements of Big Pharma with the Trump administration, strong quarterly results, bullish outlook for 2026, robust pipeline activity and a flurry of M&A deals have led to the industry’s recovery. However, it faces its share of headwinds like regular pipeline setbacks, slow ramp-up of newer drugs, patent cliffs, regulatory risks and policy and pricing uncertainty. Despite the headwinds, the industr ...